This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Meloni, F. Articles by Sciacca, A. Search for Related Content PubMed PubMed Citation Articles by Meloni, F. Articles by Sciacca, A. Social Bookmarking                         What's this?

Therapeutic Efficacy of Ketanserin, a Selective Antagonist of the Serotonin (5-HT 2) Receptors, in Primary and Secondary Raynaud's Phenomenon

From the Cattedra di IV Clinica Medica (Dirett. Prof. A. Sciacca) Università degli Studi di Roma "La Sapienza" Rome, Italy

Maria Grazia Transi

From the Cattedra di IV Clinica Medica (Dirett. Prof. A. Sciacca) Università degli Studi di Roma "La Sapienza" Rome, Italy

Vincenzo Sciacca

From the Istituto di I Clinica Chirurgica-Università degli Studi di Roma "La Sapienza" Rome, Italy

Carlo De Felice

From the Istituto di Scienza dello Sport C.O.N.I., Department of Medicine, Rome, Italy

Amedeo Bagarone

From the Istituto di Scienza dello Sport C.O.N.I., Department of Medicine, Rome, Italy

Andrea Sciacca

From the Cattedra di IV Clinica Medica (Dirett. Prof. A. Sciacca) Università degli Studi di Roma "La Sapienza" Rome, Italy

Fourteen ambulatory and hospitalized patients with primary and secondary Raynaud's phenomenon have been examined before and after a thirty-one-day therapeutic trial.

The treatment was conducted in two cycles. The first one lasted ten days, during which placebo was administered. The second cycle lasted three weeks, during which ketanserin, a selective antagonist of 5-hydroxytryptamine (5-HT₂) receptors, was administered.

The therapeutic effect consisted of the complete healing of digital ulcers in 4 of 5 patients and a considerable decrease in the number, length, and severity of daily attacks.

To evaluate the digital blood flow, each patient was submitted to a medical dynamic telethermographic test. This, after the cooling test, demonstrated an average decrease of twenty minutes in the time necessary to reestablish basal thermal conditions (T') at the end of an adequate period of therapy using optimal doses of the drug. The authors affirm that orally administered ketanserin has a beneficial effect and can be well tolerated in subjects with Raynaud's phenomenon.

Angiology, Vol. 38, No. 7, 530-536 (1987)
DOI: 10.1177/000331978703800706


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Arosio, G. Montesi, M. Zannoni, L. Perbellini, F. Paluani, and A. Lechi Efficacy of Ketanserin in the Therapy of Raynaud's Phenomenon: Thermometric Data Angiology, May 1, 1991; 42(5): 408 - 413. [Abstract] [PDF]

				E. Arosio, G. Montesi, M. Zannoni, F. Paluani, and A. Lechi Comparative Efficacy of Ketanserin and Pentoxiphylline in Treatment of Raynaud's Phenomenon Angiology, July 1, 1989; 40(7): 633 - 638. [Abstract] [PDF]